{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T01:38:04Z","timestamp":1774057084476,"version":"3.50.1"},"reference-count":64,"publisher":"S.C. JURNALUL PENTRU MEDICINA SI VIATA S.R.L","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JMedLife"],"abstract":"<jats:p>Coronavirus disease 2019 (COVID-19) is currently considered a complex systemic infectious and inflammatory disease, determined by the infection with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), and the cause of one of the most important epidemiological phenomena in the last century \u2013 the COVID-19 pandemic. This infectious-inflammatory disease may generate a wide range of clinical manifestations and biological modifications, explained by the ubiquitous nature of the SARS-CoV-2 receptors, represented by the angiotensin-converting enzyme-2 (ACE-2), and by the host\u2019s violent immune and proinflammatory reaction to the viral infection. These manifestations include immunological disturbances, which, according to certain clinical findings, may persist post-infection, in the form of a presumed systemic inflammatory entity, defined by several clinical concepts with a common pathological significance: post-COVID-19 multisystem (or systemic) inflammatory syndrome, post-COVID syndrome or long-COVID. Although the pathophysiological mechanisms of the post-COVID-19 syndrome are elusive at the present moment, there are currently several studies that describe a systemic inflammatory or autoimmune phenomenon following the remission of the COVID-19 infection in some patients, which suggests the existence of molecular and cellular immune abnormalities, most probably due to the host\u2019s initial violent immune response to the viral infection, in the form of three overlapping entities: secondary hemophagocytic lymph histiocytosis (HLH), macrophage activation syndrome (MAS) and cytokine release syndrome (CRS). Thus, this is reminiscent of different classic autoimmune diseases, in which various infections are risk factors in developing the autoimmune process.<\/jats:p>","DOI":"10.25122\/jml-2022-0329","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T06:10:04Z","timestamp":1683526204000},"page":"195-202","source":"Crossref","is-referenced-by-count":18,"title":["Post-COVID-19 syndrome: Insights into a novel post-infectious systemic disorder"],"prefix":"10.25122","volume":"16","author":[{"given":"Marilena","family":"Stoian","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Carol Davila University of Medicine and Pharmacy, Bucharest, Romania","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"* Corresponding Author: Marilena Stoian, Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania. Carol Davila University of Medicine and Pharmacy, Bucharest, Romania. E-mail: marilenastoian@yahoo.com","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bianca","family":"Procopiescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silviu","family":"\u0218eitan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriel","family":"Scarlat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Department of Internal Medicine, Dr. Ion Cantacuzino Clinical Hospital, Bucharest, Romania","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10755","published-online":{"date-parts":[[2023,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"1. Scarlat G, Dona B, Procopiescu B, Stoian M. Post-Covid-19 Immunological Disorder: A Possible Pathological Entity in a 43 Year Old Man. Internal Medicine. 2022;19(2):77-94 https:\/\/doi.org\/10.2478\/inmed-2022-0210.","DOI":"10.2478\/inmed-2022-0210"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"2. Morris SB, Schwartz NG, Patel P, Abbo L, et al. Case Series of Multisystem Inflammatory Syndrome in Adults Associated with SARS-CoV-2 Infection \u2013 United Kingdom and United States, March-August 2020. MMWR Morb Mortal Wkly Rep 2020;69:1450-1456. DOI:http:\/\/dx.doi.org\/10.15585\/ mmwr.mm6940e1external icon.","DOI":"10.15585\/mmwr.mm6940e1"},{"key":"ref3","unstructured":"3. COVID-19: long term effects. Available from: https:\/\/www.mayoclinic.org\/ diseases-conditions\/coronavirus\/in-depth\/coronavirus-long-term-effects\/ art-20490351."},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"4. Anaya JM, Herr\u00e1n M, Beltr\u00e1n S, Rojas M. Is post-COVID syndrome an autoimmune disease? Expert Rev Clin Immunol. 2022 Jul;18(7):653-666. doi: 10.1080\/1744666X.2022.2085561.","DOI":"10.1080\/1744666X.2022.2085561"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"5. Rojas M, Rodr\u00edguez Y, Acosta-Ampudia Y, Monsalve DM, et al. Autoimmunity is a hallmark of post-COVID syndrome. J Transl Med. 2022 Mar 16;20(1):129. doi: 10.1186\/s12967-022-03328-4","DOI":"10.1186\/s12967-022-03328-4"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"6. Acosta-Ampudia Y, Monsalve DM, Rojas M, Rodr\u00edguez Y, et al. Persistent Autoimmune Activation and Proinflammatory State in Post-Coronavirus Disease 2019 Syndrome. J Infect Dis. 2022 Jun 15;225(12):2155-2162. doi: 10.1093\/infdis\/jiac017","DOI":"10.1093\/infdis\/jiac017"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"7. Fajgenbaum DC, June CH. Cytokine Storm. N Engl J Med. 2020 Dec 3;383(23):2255-2273. doi: 10.1056\/NEJMra2026131.","DOI":"10.1056\/NEJMra2026131"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"8. Ros\u00e1rio C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22;11:185. doi: 10.1186\/1741-7015-11-185.","DOI":"10.1186\/1741-7015-11-185"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"9. Shoenfeld Y. Corona (COVID-19) time musings: Our involvement in COVID-19 pathogenesis, diagnosis, treatment and vaccine planning. Autoimmun Rev. 2020 Jun;19(6):102538. doi: 10.1016\/j.autrev.2020.102538.","DOI":"10.1016\/j.autrev.2020.102538"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"10. Kumar B, Aleem S, Saleh H, Petts J, Ballas ZK. A Personalized Diagnostic and Treatment Approach for Macrophage Activation Syndrome and Secondary Hemophagocytic Lymphohistiocytosis in Adults. J Clin Immunol. 2017 Oct;37(7):638-643. doi: 10.1007\/s10875-017-0439-x.","DOI":"10.1007\/s10875-017-0439-x"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"11. Usmani GN, Woda BA, Newburger PE. Advances in understanding the pathogenesis of HLH. Br J Haematol. 2013 Jun;161(5):609-22. doi: 10.1111\/ bjh.12293.","DOI":"10.1111\/bjh.12293"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"12. Lee DW, Gardner R, Porter DL, Louis CU, et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014 Jul 10;124(2):188-95. doi: 10.1182\/blood-2014-05-552729.","DOI":"10.1182\/blood-2014-05-552729"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"13. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125:2908\u201314. https:\/\/doi.org\/10.1182\/ blood-2015-01-551622","DOI":"10.1182\/blood-2015-01-551622"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"14. Ramos-Casals M, Brito-Zer\u00f3n P, L\u00f3pez-Guillermo A, Khamashta MA, Bosch X. Adult haemophagocytic syndrome. Lancet. 2014 Apr 26;383(9927):1503-1516. doi: 10.1016\/S0140-6736(13)61048-X.","DOI":"10.1016\/S0140-6736(13)61048-X"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"15. Rekha TS, Kiran HS, Nandini NM, Murthy S. Cytology of secondary hemophagocytic lymphohistiocytosis masquerading as lymphoma in a nonimmunocompromised adult. J Cytol. 2014 Oct-Dec;31(4):239-41. doi: 10.4103\/0970-9371.151146.","DOI":"10.4103\/0970-9371.151146"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"16. Sieni E, Cetica V, Piccin A, Gherlinzoni F, et al. Familial hemophagocytic lymphohistiocytosis may present during adulthood: clinical and genetic features of a small series. PLoS One. 2012;7(9):e44649. doi: 10.1371\/journal. pone.0044649","DOI":"10.1371\/journal.pone.0044649"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"17. Parodi A, Dav\u00ec S, Pringe AB, Pistorio A, et al. Macrophage activation syndrome in juvenile systemic lupus erythematosus: a multinational multicenter study of thirty-eight patients. Arthritis Rheum. 2009 Nov;60(11):3388-99. doi: 10.1002\/art.24883","DOI":"10.1002\/art.24883"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"18. Cortis E, Insalaco A. Macrophage activation syndrome in juvenile idiopathic arthritis. Acta Paediatr Suppl. 2006 Jul;95(452):38-41. doi: 10.1080\/08035320600649713.","DOI":"10.1111\/j.1651-2227.2006.tb02414.x"},{"key":"ref19","unstructured":"19. Celkan T, Berrak S, Kazanci E, Ozy\u00fcrek E, et al. Malignancy-associated hemophagocytic lymphohistiocytosis in pediatric cases: a multicenter study from Turkey. Turk J Pediatr. 2009 May-Jun;51(3):207-13."},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"20. Kelesidis T, Humphries R, Terashita D, Eshaghian S, et al. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in Los Angeles County. J Med Virol. 2012 May;84(5):777-85. doi: 10.1002\/jmv.23267.","DOI":"10.1002\/jmv.23267"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"21. Quan C, Li C, Ma H, Li Y, Zhang H. Immunopathogenesis of Coronavirus-Induced Acute Respiratory Distress Syndrome (ARDS): Potential Infection-Associated Hemophagocytic Lymphohistiocytosis. Clin Microbiol Rev. 2020 Oct 14;34(1):e00074-20. doi: 10.1128\/CMR.00074-20.","DOI":"10.1128\/CMR.00074-20"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"22. Bracaglia C, Prencipe G, De Benedetti F. Macrophage Activation Syndrome: different mechanisms leading to a one clinical syndrome. Pediatr Rheumatol Online J. 2017 Jan 17;15(1):5. doi: 10.1186\/s12969-016-0130-4.","DOI":"10.1186\/s12969-016-0130-4"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"23. Wu C, Chen X, Cai Y, Xia J, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Jul 1;180(7):934-943. doi: 10.1001\/jamainternmed.2020.0994.","DOI":"10.1001\/jamainternmed.2020.0994"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"24. McGonagle D, Sharif K, O'Regan A, Bridgewood C. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020 Jun;19(6):102537. doi: 10.1016\/j.autrev.2020.102537","DOI":"10.1016\/j.autrev.2020.102537"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"25. N\u00fa\u00f1ez-Torr\u00f3n C, Ferrer-G\u00f3mez A, Moreno Moreno E, P\u00e9rez-Mies B, et al. Secondary haemophagocytic lymphohistiocytosis in COVID-19: correlation of the autopsy findings of bone marrow haemophagocytosis with HScore. J Clin Pathol. 2022 Jun;75(6):383-389. doi: 10.1136\/jclinpath-2020-207337","DOI":"10.1136\/jclinpath-2020-207337"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"26. Bergsten E, Horne A, Aric\u00f3 M, Astigarraga I, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017 Dec 21;130(25):2728-2738. doi: 10.1182\/blood-2017-06-788349.","DOI":"10.1182\/blood-2017-06-788349"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"27. Lima R, Filho CC, Filho CMF, Vaisman M, et al. Hemophagocytic syndrome and COVID-19. Respiratory Medicine Case Reports. 2020;31:2213-0071. https:\/\/doi.org\/10.1016\/j.rmcr.2020.101162.","DOI":"10.1016\/j.rmcr.2020.101162"},{"key":"ref28","doi-asserted-by":"crossref","unstructured":"28. Kalita P, Laishram D, Dey B, Mishra J, et al. Secondary Hemophagocytic Lymphohistiocytosis in Post-COVID-19 Patients: A Report of Two Cases. Cureus. 2021 Aug 20;13(8):e17328. doi: 10.7759\/cureus.17328.","DOI":"10.7759\/cureus.17328"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"29. Zhou Y, Han T, Chen J, Hou C, et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin Transl Sci. 2020 Nov;13(6):1077-1086. doi: 10.1111\/cts.12805.","DOI":"10.1111\/cts.12805"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"30. Vlachoyiannopoulos PG, Magira E, Alexopoulos H, Jahaj E, Theophilopoulou K, Kotanidou A, Tzioufas AG. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020 Dec;79(12):1661-1663. doi: 10.1136\/annrheumdis-2020-218009.","DOI":"10.1136\/annrheumdis-2020-218009"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"31. Bomhof G, Mutsaers PGNJ, Leebeek FWG, Te Boekhorst PAW, et al. COVID-19-associated immune thrombocytopenia. Br J Haematol. 2020 Jul;190(2):e61-e64. doi: 10.1111\/bjh.16850.","DOI":"10.1111\/bjh.16850"},{"key":"ref32","doi-asserted-by":"crossref","unstructured":"32. Zulfiqar AA, Lorenzo-Villalba N, Hassler P, Andr\u00e8s E. Immune Thrombocytopenic Purpura in a Patient with Covid-19. N Engl J Med. 2020 Apr 30;382(18):e43. doi: 10.1056\/NEJMc2010472.","DOI":"10.1056\/NEJMc2010472"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"33. Angileri F, L\u00e9gar\u00e9 S, Marino Gammazza A, Conway de Macario E, et al. Is molecular mimicry the culprit in the autoimmune haemolytic anaemia affecting patients with COVID-19? Br J Haematol. 2020 Jul;190(2):e92-e93. doi: 10.1111\/bjh.16883.","DOI":"10.1111\/bjh.16883"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"34. Angileri F, Legare S, Marino Gammazza A, Conway de Macario E, et al. Molecular mimicry may explain multi-organ damage in COVID-19. Autoimmun Rev. 2020 Aug;19(8):102591. doi: 10.1016\/j.autrev.2020.102591.","DOI":"10.1016\/j.autrev.2020.102591"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"35. Moody R, Wilson K, Flanagan KL, Jaworowski A, Plebanski M. Adaptive Immunity and the Risk of Autoreactivity in COVID-19. Int. J. Mol. Sci. 2021;22:8965. https:\/\/doi.org\/10.3390\/ ijms22168965","DOI":"10.3390\/ijms22168965"},{"key":"ref36","unstructured":"36. COVID Symptom Study. How Long Does COVID-19 Last? Available from: https:\/\/covid19.joinzoe.com\/post\/covid-long-term?fbclid=IwAR1RxI cmmdL-EFjh_aI-"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"37. Bektas A, Schurman SH, Franceschi C, Ferrucci L. A public health perspective of aging: do hyper-inflammatory syndromes such as COVID-19, SARS, ARDS, cytokine storm syndrome, and post-ICU syndrome accelerate short- and long-term inflammaging? Immun Ageing. 2020 Aug 24;17:23. doi: 10.1186\/s12979-020-00196-8.","DOI":"10.1186\/s12979-020-00196-8"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"38. Damoiseaux J, Dotan A, Fritzler MJ, Bogdanos DP, et al. Autoantibodies and SARS-CoV2 infection: The spectrum from association to clinical implication: Report of the 15th Dresden Symposium on Autoantibodies. Autoimmun Rev. 2022 Mar;21(3):103012. doi: 10.1016\/j.autrev.2021.103012.","DOI":"10.1016\/j.autrev.2021.103012"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"39. Vojdani A, Vojdani E, Kharrazian D. Reaction of Human Monoclonal Antibodies to SARS-CoV-2 Proteins With Tissue Antigens: Implications for Autoimmune Diseases. Front Immunol. 2021 Jan 19;11:617089. doi: 10.3389\/fimmu.2020.617089.","DOI":"10.3389\/fimmu.2020.617089"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"40. Chang SE, Feng A, Meng W, Apostolidis SA, et al. New-onset IgG autoantibodies in hospitalized patients with COVID-19. Nat Commun. 2021;12:5417. https:\/\/doi.org\/10.1038\/s41467-021-25509-3","DOI":"10.1038\/s41467-021-25509-3"},{"key":"ref41","unstructured":"41. Wang EY, Mao T, Klein J, Day Y, et al. Diverse functional autoantibodies in patients with COVID-19. Nature. 2021;595:283\u2013288. https:\/\/doi. org\/10.1038\/s41586-021-03631-y"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"42. Knight JS, Caricchio R, Casanova JL, Combes AJ, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021 Dec 15;131(24):e154886. doi: 10.1172\/JCI154886.","DOI":"10.1172\/JCI154886"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"43. Ca\u00f1as CA. The triggering of post-COVID-19 autoimmunity phenomenon could be associated with both transient immunosupression and an inappropriate form of immune reconstitution in susceptible individuals. Med Hypotheses. 2020 Dec;145:110345. doi: 10.1016\/j.mehy.2020.110345.","DOI":"10.1016\/j.mehy.2020.110345"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"44. Diao B, Wang C, Tan Y, Chen X, et al. Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19). Front Immunol. 2020 May 1;11:827. doi: 10.3389\/fimmu.2020.00827.","DOI":"10.3389\/fimmu.2020.00827"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"45. Ros\u00e1rio C, Zandman-Goddard G, Meyron-Holtz EG, D'Cruz DP, Shoenfeld Y. The hyperferritinemic syndrome: macrophage activation syndrome, Still's disease, septic shock and catastrophic antiphospholipid syndrome. BMC Med. 2013 Aug 22;11:185. doi: 10.1186\/1741-7015-11-185.","DOI":"10.1186\/1741-7015-11-185"},{"key":"ref46","doi-asserted-by":"crossref","unstructured":"46. Jabeen R, Kaplan MH. The symphony of the ninth: the development and function of Th9 cells. Curr Opin Immunol. 2012 Jun;24(3):303-7. doi: 10.1016\/j.coi.2012.02.001.","DOI":"10.1016\/j.coi.2012.02.001"},{"key":"ref47","doi-asserted-by":"crossref","unstructured":"47. Orologas-Stavrou N, Politou M, Rousakis P, Kostopoulos IV, et al. Peripheral Blood Immune Profiling of Convalescent Plasma Donors Reveals Alterations in Specific Immune Subpopulations Even at 2 Months Post SARS-CoV-2 Infection. Viruses. 2020 Dec 25;13(1):26. doi: 10.3390\/v13010026.","DOI":"10.3390\/v13010026"},{"key":"ref48","doi-asserted-by":"crossref","unstructured":"48. Pal R. COVID-19, hypothalamo-pituitary-adrenal axis and clinical implications. Endocrine. 2020;68:251\u2013252. https:\/\/doi.org\/10.1007\/s12020-020-02325-1","DOI":"10.1007\/s12020-020-02325-1"},{"key":"ref49","doi-asserted-by":"crossref","unstructured":"49. Wheatland R. Molecular mimicry of ACTH in SARS - implications for corticosteroid treatment and prophylaxis. Med Hypotheses. 2004;63(5):855-62. doi: 10.1016\/j.mehy.2004.04.009.","DOI":"10.1016\/j.mehy.2004.04.009"},{"key":"ref50","doi-asserted-by":"crossref","unstructured":"50. Ding Y, He L, Zhang Q , Huang Z, et al. Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways. J Pathol. 2004 Jun;203(2):622-30. doi: 10.1002\/path.1560.","DOI":"10.1002\/path.1560"},{"key":"ref51","doi-asserted-by":"crossref","unstructured":"51. Freire Santana M, Borba MGS, Ba\u00eda-da-Silva DC, Val F, et al. Case report: adrenal pathology findings in severe COVID-19: an autopsy study. Am J Trop Med Hygiene. 2020;103(4):1604\u20137. doi: 10.4269\/ajtmh.20-0787.","DOI":"10.4269\/ajtmh.20-0787"},{"key":"ref52","doi-asserted-by":"crossref","unstructured":"52. Hanley B, Naresh KN, Roufosse C, Nicholson AG, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. Lancet Microbe. 2020;1(6):e245\u201353. https:\/\/doi. org\/10.1016\/S2666-5247(20)30115-4","DOI":"10.1016\/S2666-5247(20)30115-4"},{"key":"ref53","doi-asserted-by":"crossref","unstructured":"53. Sharrack N, Baxter CT, Paddock M, Uchegbu E. Adrenal haemorrhage as a complication of COVID-19 infection. BMJ Case Reports CP. 2020;13(11):e239643. https:\/\/doi.org\/10.1136\/bcr-2020-239643.","DOI":"10.1136\/bcr-2020-239643"},{"key":"ref54","doi-asserted-by":"crossref","unstructured":"54. Frankel M, Feldman I, Levine M, Frank Y, Bogot NR, Benjaminov O, et al. Bilateral adrenal hemorrhage in coronavirus disease 2019 patient: a case report. J Clin Endocrinol Metabol 2020;105(12):3745-9.","DOI":"10.1210\/clinem\/dgaa487"},{"key":"ref55","doi-asserted-by":"crossref","unstructured":"55. Kumar R, Guruparan T, Siddiqi S, Sheth R, et al. A case of adrenal infarction in a patient with COVID 19 infection. BJR| case reports. 2020;6 (3):20200075. https:\/\/doi.org\/10.1259\/bjrcr.20200075.","DOI":"10.1259\/bjrcr.20200075"},{"key":"ref56","doi-asserted-by":"crossref","unstructured":"56. Costa BA, da Luz KV, Campos SEV, Lopes GS, et al. Can SARS-CoV-2 induce hematologic malignancies in predisposed individuals? A case series and review of the literature. Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):26-31. doi: 10.1016\/j.htct.2021.11.015.","DOI":"10.1016\/j.htct.2021.11.015"},{"key":"ref57","doi-asserted-by":"crossref","unstructured":"57. Rivellese F, Prediletto E. ACE2 at the centre of COVID-19 from paucisymptomatic infections to severe pneumonia. Autoimmun Rev. 2020 Jun;19(6):102536. doi: 10.1016\/j.autrev.2020.102536.","DOI":"10.1016\/j.autrev.2020.102536"},{"key":"ref58","doi-asserted-by":"crossref","unstructured":"58. Cheng H, Wang Y, Wang GQ. Organ-protective effect of angiotensinconverting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol. 2020 Jul;92(7):726-730. doi: 10.1002\/jmv.25785","DOI":"10.1002\/jmv.25785"},{"key":"ref59","unstructured":"59. Haznedaroglu IC, Malkan UY. Local bone marrow renin-angiotensin system in the genesis of leukemia and other malignancies. Eur Rev Med Pharmacol Sci. 2016 Oct;20(19):4089-4111"},{"key":"ref60","unstructured":"60. Beyazit Y, Aksu S, Haznedaroglu IC, Kekilli M, et al. Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J Natl Med Assoc. 2007;99(1):57-63. https:\/\/doi.org\/10.1182\/blood. V106.11.4567.4567"},{"key":"ref61","doi-asserted-by":"crossref","unstructured":"61. Rodgers KE, Xiong S, Steer R, diZerega GS. Effect of angiotensin II on hematopoietic progenitor cell proliferation. Stem Cells. 2000;18(4):287-94. doi: 10.1634\/stemcells.18-4-287","DOI":"10.1634\/stemcells.18-4-287"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"62. De la Iglesia I\u00f1igo S, L\u00f3pez-Jorge CE, G\u00f3mez-Casares MT, Lemes Castellano A, et al. Induction of apoptosis in leukemic cell lines treated with captopril, trandolapril and losartan: a new role in the treatment of leukaemia for these agents. Leuk Res. 2009 Jun;33(6):810-6. doi: 10.1016\/j.leukres.2008.09.029.","DOI":"10.1016\/j.leukres.2008.09.029"},{"key":"ref63","doi-asserted-by":"crossref","unstructured":"63. Kozako T, Soeda S, Yoshimitsu M, Arima N, et al. Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells. FEBS Open Bio. 2016 Apr 13;6(5):442-60. doi: 10.1002\/2211-5463.12055","DOI":"10.1002\/2211-5463.12055"},{"key":"ref64","unstructured":"64. Long-term effects of coronavirus (long COVID). Available from: https:\/\/ www.nhs.uk\/conditions\/coronavirus-covid-19\/long-term-effects-ofcoronavirus-long-covid\/"}],"container-title":["Journal of Medicine and Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/8.-jml-2022-0329.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T06:10:28Z","timestamp":1683526228000},"score":1,"resource":{"primary":{"URL":"https:\/\/medandlife.org\/wp-content\/uploads\/8.-jml-2022-0329.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":64,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["JMedLife-16-195"],"URL":"https:\/\/doi.org\/10.25122\/jml-2022-0329","relation":{},"ISSN":["1844-122X","1844-3117"],"issn-type":[{"value":"1844-122X","type":"print"},{"value":"1844-3117","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2]]}}}